It is important to know whether you have a triple negative breast cancer before undergoing treatment. This type of breast cancer is aggressive, resulting in a greater likelihood of metastasizing outside of the breast. Moreover, triple negative cancers tend to recur within three years of treatment and are fatal within five years. To make sure you get the best treatment possible, it is vital to seek a medical expert’s advice.
Treatment options for triple-negative breast cancer are quite varied. Chemotherapy is the standard of care for advanced stages of the disease. It is also recommended up-front, as early treatment will allow the clinician to monitor how the tumor responds to the treatment and determine whether further action is necessary. If, however, the cancer has returned, other treatments may be necessary. It is also important to understand that treatment for triple-negative breast cancer is not the same for every type of tumor.
Treatment options for triple-negative breast cancer vary greatly, with some women responding well to standard treatments. However, some women remain resistant to treatments despite standard care. Fortunately, research is starting to crack the code. Treatment options for TNBC are limited compared to treatments for other types of breast cancer. As of now, however, the most effective treatments are still being developed. However, if you have a triple-negative tumor, there is hope for you. You may qualify for a clinical trial.
Although triple-negative breast cancer is more likely to recur than other forms of breast cancer, patients with this subtype often have a shorter survival time than other types. This subtype accounts for up to a fifth of all breast cancer cases, so knowing its imaging characteristics can help you provide better care for your patients. In addition, the study also reveals important information about the disease itself. You should be aware of what you can and cannot do to prevent it from coming back.
Treatment options for triple-negative breast cancer vary based on the histological type. Metaplastic and adenoid cystic carcinomas were the most common triple-negative types. In a Phase 1 clinical trial, Dr. Tchou and Paul J.L. Zhang discovered that up to 60 percent of triple-negative breast cancer patients had this marker. The researchers concluded that this marker is highly relevant for a high-risk patient with a triple-negative tumor.
The risk of developing this type of breast cancer is significantly higher among Hispanic women. The risk of triple-negative breast cancer is also higher among Hispanic women than in Caucasians. However, these cancers may be a result of a mutation of the BRCA1 gene, which helps the cells in the body produce tumor-suppressant proteins. Although there is no conclusive evidence regarding the cause of triple-negative breast cancer, lifestyle factors are known to reduce risk.
Unlike other types of breast cancer, triple-negative cancers do not express HER2, estrogen or progesterone receptors. This means that hormonal therapies are unlikely to work on these cancers. Treatments for triple-negative cancers are limited to surgery, chemotherapy, or radiotherapy. Although triple-negative cancers do not respond to hormonal therapies, they are still effective for a small proportion of women. It is important to understand what makes triple-negative breast cancer different from other types of breast cancer.
